drugset / Trial / NCT05432518
Pilot Trial for Treatment of Recurrent Glioblastoma
NaSingle-groupOpen-labelTreatment
Summary
This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their recurrent GBM tumor resected at the time of surgery. It will be aimed to gather preliminary information on the study intervention and the feasibility of conducting a full-scale trial.
Timeline
- Start
- 2023-06-27
- Primary completion
- 2027-07-01
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 40 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | Palbociclib | Small molecule | 125 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |